Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TO O 1001

Next Previous
X
Search
Drug Profile

TO O 1001

Alternative Names: MG-O-1001; TO-O-1001

Latest Information Update: 11 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theratocular Biotek
  • Developer Novotech; Theratocular Biotek
  • Class Antiglaucomas; Eye disorder therapies
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glaucoma; Ocular hypertension

Most Recent Events

  • 06 Dec 2023 Metagone Biotech plans a phase III trial for Glaucoma in Q4 in 2023 (Metagone Biotech pipeline, December 2023)
  • 07 Sep 2022 Metagone Biotech plans a phase I/II trial for Glaucoma in Australia (Ophthalmic) in Q2 2023 (NCT05456724) (Theratocular Biotek pipeline, September 2022)
  • 07 Sep 2022 Theratocular Biotek plans to submit regulatory application to initiate phase I/II trial in Glaucoma (Theratocular Biotek pipeline, September 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top